LegoChem Entered into a Research Collaboration and License Agreement with Glycotope to Develop ADCs for the Treatment of Cancer
Shots:
- Following the successful completion of a feasibility study, LCB gets exclusive rights globally to exercise its option to develop & commercialize the selected Abs as ADC. If LCB exercises these rights, Glycotope to receive an up front, development & sales milestones along with royalties
- The collaboration will combine LCB’s ADC technology platform with Glycotope's tumor-targeting Abs to develop ADCs for cancer patients. The collaboration further highlights the significance of Glycotope's distinct technological platform & strengthens Glycotope’s position in the creation of highly selective glyco-epitope targeting Abs
- The companies are planning to advance the program to the clinical stage as a competitive cancer therapy
Ref: Globenewswire| Image: LegoChem
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
